Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients
Authors:
- 1 July 2021
- journal article
- review article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 356, 577599
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- The effect of rituximab on vaccine responses in patients with immune thrombocytopeniaBlood, 2013
- Immune competence after alemtuzumab treatment of multiple sclerosisNeurology, 2013
- Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosisNeurology, 2013
- Humoral-Targeted Immunotherapies in Multiple SclerosisNeurotherapeutics, 2013
- Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatmentBlood, 2011
- The Mechanism of Action of Interferon-β in Relapsing Multiple SclerosisCNS Drugs, 2011
- Glatiramer Acetate in the Treatment of Multiple SclerosisCNS Drugs, 2011
- Fundamentals of Vaccine ImmunologyJournal of Global Infectious Diseases, 2011
- Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1aNeurology, 2005
- TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITYAnnual Review of Immunology, 2005